Pfizer is going through a big change. They are still trying to recover from the post-pandemic market. This is happening as COVID-19 revenues decline. It’s stock price trades in the mid 20’s through the first half of 2025, down 10% from the beginning of the year, and 23.3 below its 52 week high. With a strong dividend yield, Pfizer is an attractive for buying opportunities for income-focused investors; however, regulatory uncertainties warrant consideration.
In the first quarter of 2025, Pfizer reported revenues of $13.72 billion. This is an 8 percent decrease from last year. The drop is mainly due to a 75 percent fall in Paxlovid sales. The company has seen a drop in sales because of lower COVID-19 revenues. As a result, it is focusing on cutting costs and developing new products.
The company plans to save $4.5 billion by the end of fiscal year 2025. They expect to save another $1.2 billion by 2027. Savings are expected on the back of digital enablement, business simplification, and automation through AI.
Pfizer Daily Chart
When we look at Pfizer’s daily chart, short-term signals favor buyers. The price is above its 10-day moving average, and the RSI is moving sideways. It is worth noting however that medium and long term moving averages indicate caution is warranted.
Strong support is eyed at $21.50-22.00 range, with notable resistance at $25.50 ceiling. The MACD is slightly above negative territory, suggesting bearish crossover if downside momentum continues. The RSI is now at 56. This shows that prices are moving sideways. Momentum is neither overbought nor oversold.
Explore More on Sigmanomics
Read more
https://www.nasdaq.com/articles/do-wall-street-analysts-pfizer-stock
Pfizer Stock Price Quote – NYSE: PFE | Morningstar
Pfizer (PFE) Stock Forecast, Price Targets and Analysts Predictions – TipRanks.com
Ronald Francois
Ronald is a senior market strategist at Sigmanomics.com, bringing over a decade of hands-on experience in equity markets and three years of specialized expertise in options trading. Known for his sharp fundamental analysis and deep understanding of macroeconomic trends, Ronald provides readers with actionable insights that bridge the gap between institutional strategy and individual investor needs.
